KURA ONCOLOGY, INC. Investing Cash Flow
KURA ONCOLOGY, INC. (KURA) reported Investing Cash Flow of $67.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $92.21M, a 56.44% increase year-over-year.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$24.23M.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$64.60M.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $93.97M, a 106.36% increase year-over-year.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$13.10M.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$101.59M, a 753.02% decline from fiscal 2023.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities for fiscal 2023 was $15.56M, a 52.32% decline from fiscal 2022.
- KURA ONCOLOGY, INC. net cash provided by (used in) investing activities for fiscal 2022 was $32.63M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $92.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $67.98M 10-Q · filed 2026-08-12 | $3.38M derived: sum of 3 quarters · filed 2026-08-12 | $97.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$24.23M 10-Q · filed 2026-05-12 | -$88.83M derived: sum of 2 quarters · filed 2026-05-12 | $5.14M derived: sum of 3 quarters · filed 2026-05-12 | $64.08M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$64.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $29.37M derived: sum of 2 quarters · filed 2026-03-05 | $88.31M derived: sum of 3 quarters · filed 2026-08-12 | -$13.10M 10-K · filed 2026-03-05 |
| 2025-09-30 | $93.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $152.91M derived: sum of 2 quarters · filed 2026-08-12 | $51.50M 10-Q · filed 2025-11-04 | -$43.46M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $58.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$42.47M 10-Q · filed 2026-08-12 | -$137.42M derived: sum of 3 quarters · filed 2026-08-12 | -$91.89M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$101.41M 10-Q · filed 2026-05-12 | -$196.36M derived: sum of 2 quarters · filed 2026-05-12 | -$150.83M derived: sum of 3 quarters · filed 2026-05-12 | -$107.66M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$94.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$49.42M derived: sum of 2 quarters · filed 2026-03-05 | -$6.25M derived: sum of 3 quarters · filed 2026-03-05 | -$101.59M 10-K · filed 2026-03-05 |
| 2024-09-30 | $45.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $88.70M derived: sum of 2 quarters · filed 2025-11-04 | -$6.63M 10-Q · filed 2025-11-04 | $35.56M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $43.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$52.17M 10-Q · filed 2025-08-07 | -$9.97M derived: sum of 3 quarters · filed 2026-03-05 | -$1.42M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | -$95.34M 10-Q · filed 2025-05-01 | -$53.14M derived: sum of 2 quarters · filed 2026-03-05 | -$44.58M derived: sum of 3 quarters · filed 2026-03-05 | -$90.91M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $42.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $50.75M derived: sum of 2 quarters · filed 2026-03-05 | $4.43M derived: sum of 3 quarters · filed 2026-03-05 | $15.56M 10-K · filed 2026-03-05 |
| 2023-09-30 | $8.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$37.77M derived: sum of 2 quarters · filed 2024-11-07 | -$26.64M 10-Q · filed 2024-11-07 | -$73.96M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$46.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$35.20M 10-Q · filed 2024-08-08 | -$82.52M derived: sum of 3 quarters · filed 2025-02-28 | -$10.71M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $11.13M 10-Q · filed 2024-05-02 | -$36.19M derived: sum of 2 quarters · filed 2025-02-28 | $35.62M derived: sum of 3 quarters · filed 2025-02-28 | $68.72M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$47.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $24.49M derived: sum of 2 quarters · filed 2025-02-28 | $57.59M derived: sum of 3 quarters · filed 2025-02-28 | $32.63M 10-K · filed 2025-02-28 |
| 2022-09-30 | $71.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $104.91M derived: sum of 2 quarters · filed 2023-11-02 | $79.94M 10-Q · filed 2023-11-02 | $154.01M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $33.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $8.13M 10-Q · filed 2023-08-09 | $82.20M derived: sum of 3 quarters · filed 2024-02-27 | $104.74M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$24.96M 10-Q · filed 2023-05-10 | $49.10M derived: sum of 2 quarters · filed 2024-02-27 | $71.64M derived: sum of 3 quarters · filed 2024-02-27 | $34.42M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $74.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $96.61M derived: sum of 2 quarters · filed 2024-02-27 | $59.38M derived: sum of 3 quarters · filed 2024-02-27 | -$126.83M 10-K · filed 2024-02-27 |
| 2021-09-30 | $22.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$14.68M derived: sum of 2 quarters · filed 2022-11-03 | -$200.90M 10-Q · filed 2022-11-03 | -$261.09M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$37.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$223.44M 10-Q · filed 2022-08-03 | -$283.63M derived: sum of 3 quarters · filed 2023-02-23 | -$329.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$186.22M 10-Q · filed 2022-05-04 | -$246.41M derived: sum of 2 quarters · filed 2023-02-23 | -$291.93M derived: sum of 3 quarters · filed 2023-02-23 | -$313.62M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$60.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$105.71M derived: sum of 2 quarters · filed 2023-02-23 | -$127.40M derived: sum of 3 quarters · filed 2023-02-23 | -$99.94M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$45.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$67.21M derived: sum of 2 quarters · filed 2021-11-04 | -$39.75M 10-Q · filed 2021-11-04 | -$55.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$21.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $5.77M 10-Q · filed 2021-08-05 | -$9.48M derived: sum of 3 quarters · filed 2022-02-24 | -$65.23M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $27.46M 10-Q · filed 2021-05-06 | $12.20M derived: sum of 2 quarters · filed 2022-02-24 | -$43.55M derived: sum of 3 quarters · filed 2022-02-24 | -$34.67M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$15.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$71.01M derived: sum of 2 quarters · filed 2022-02-24 | -$62.13M derived: sum of 3 quarters · filed 2022-02-24 | -$46.33M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$55.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$46.88M derived: sum of 2 quarters · filed 2020-11-05 | -$31.07M 10-Q · filed 2020-11-05 | -$26.45M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $8.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $24.68M 10-Q · filed 2020-08-06 | $29.30M derived: sum of 3 quarters · filed 2021-02-24 | -$28.76M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $15.81M 10-Q · filed 2020-05-04 | $20.43M derived: sum of 2 quarters · filed 2021-02-24 | -$37.63M derived: sum of 3 quarters · filed 2021-02-24 | -$33.78M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$53.44M derived: sum of 2 quarters · filed 2021-02-24 | -$49.59M derived: sum of 3 quarters · filed 2021-02-24 | -$79.30M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$58.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$54.20M derived: sum of 2 quarters · filed 2019-11-05 | -$83.92M 10-Q · filed 2019-11-05 | -$88.01M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $3.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$25.86M 10-Q · filed 2019-08-01 | -$29.95M derived: sum of 3 quarters · filed 2020-02-25 | -$66.24M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | -$29.71M 10-Q · filed 2019-05-07 | -$33.80M derived: sum of 2 quarters · filed 2020-02-25 | -$70.10M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-31 | -$4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$40.38M derived: sum of 2 quarters · filed 2020-02-25 | -$23.42M 10-K · filed 2020-02-25 | |
| 2017-09-30 | -$36.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$19.33M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $16.97M 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |